Ca:Mg Ratio and Cognitive Function

Vanderbilt University Medical Center

Status: Completed

Conditions: Cognitive Function

Treatments: Dietary Supplement: Magnesium glycinate; Dietary Supplement: Placebo

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT04196023

100106a

R01CA202936 (U.S. NIH Grant/Contract)

R01CA149633 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Between 2000 and 2015, mortality due to Alzheimer's disease (AD) increased by 123%. No drugs have yet been approved to stop or slow the progression of AD. A delay of five years in the expression of AD would reduce the incidence rate by half. Thus, it is critical to develop novel prevention strategies to delay the onset of this common disease.

As an ancillary study conducted within a precision-based randomized trial (R01CA149633; PI, Dai & Yu]"), the investigators reduced Ca:Mg ratios to 2.3 through 3-month personalized Mg supplementation among those who consumed high Ca:Mg ratio diet, but otherwise in good general health. The investigators test the hypothesis that actively reducing the Ca:Mg ratio among those aged >65 years who consume high Ca:Mg ratio diets improves cognitive function compared to the placebo arm. The investigators further conduct molecular epidemiologic studies to understand the molecular mechanisms.

Enrollment: 129 patients

Sex: All

Ages: 40 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Participants from our parent study (Personalized Prevention of Colorectal Cancer Trial, NCT#01105169, IRB#100106);
2. Participants who completed the MoCA

Exclusion criteria

1. Participants did not provide their blood samples in the parent study.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

129 participants in 2 patient groups, including a placebo group

magnesium treatment

Active Comparator group

Description:

Participants will be assigned to magnesium glycinate

Treatment:

Dietary Supplement: Placebo

Dietary Supplement: Magnesium glycinate

placebo

Placebo Comparator group

Description:

Participants will be assigned to placebo group

Treatment:

Dietary Supplement: Placebo

Dietary Supplement: Magnesium glycinate